Trial Profile
A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs HTL 18318 (Primary)
- Indications Lewy body disease
- Focus Adverse reactions
- Sponsors Heptares Therapeutics; Nxera Pharma; Sosei
- 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
- 30 Sep 2019 Status changed from suspended to withdrawn prior to enrolment.
- 07 May 2019 Planned initiation date changed from 1 Aug 2018 to 1 Jul 2019.